New frontiers in COPD — what’s next on the treatment horizon?


  • Aruni S. Arachchige Don, PhD, Senior Consultant, Defined Health Inc, a Cello Health business


  • Robert Vender, M.D., F.A.C.P. Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Penn State Milton S. Hershey Medical Center
  • Irfan Rahman, PhD, Professor, Department of Medicine, Pulmonary Diseases and Critical Care, University of Rochester Medical Center

Despite significant and growing costs associated with COPD (15 million diagnosed patients in the US and 65 million WW in 2017 with 25% growth in prevalence expected in the US and EU5 through 2033, coupled with documented high costs of care), pharmacologic management of COPD has been without any major breakthrough treatments for the past two to three decades. Current therapies do not reverse the underlying scarring of the lung and airways, but are used to relieve symptoms and potentially lead to decreased exacerbations and hospitalizations. The historic lack of pharmacological innovation in this space is somewhat understandable given the current state of the disease knowledge, but nonetheless, it is concerning considering the anticipated healthcare burden this disease will have globally over the next decade.

The good news is that there finally appears to be a growing cadre of novel therapies with new mechanisms and targets in development for COPD, as well as an effort to stratify and study patient subsets in large observational studies such as (ECLIPSE, SPIROMICS, and COPDGene) in order to cluster patients into groups to identify potential biomarkers for COPD. Identification of biomarkers and characterization of phenotypes to predict response to therapy remains an active area of research in COPD. And, while disease modification remains the “holy grail,” there is also renewed focus on management of co-morbidities that have a significant impact on patient outcomes (e.g., functional impairment and mortality as well as the systemic effects of COPD).

In this webinar, Aruni Arachchige Don will lead a collegial, in-depth discussion with our panelists, Drs. Robert Vender and Irfan Rahman, focusing on new frontiers in COPD and what we can expect in terms of the evolving treatment in this space in the coming years.